

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003183

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/5517 A61P35/00 C07D487/06  
/(C07D487/06,223:00,209:00),(C07D487/06,243:00,235:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/16136 A (CANCER RES CAMPAIGN TECH ; AGOURON PHARMA (US)) 8 March 2001 (2001-03-08) cited in the application	6,7, 9-13,15, 16, 18-20, 22-24, 27-32
Y	claims 2,3,6,10; examples 58,141 page 14, line 18; example 98	1,4,5,8, 11-14, 17,20, 21,24, 25,28-30
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

25 January 2005

Date of mailing of the international search report

23/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Härtinger, S

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003183

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/42040 A (CANCER RES CAMPAIGN TECH ; CANAN KOCH STACIE S (US); WEBBER STEPHEN EV) 20 July 2000 (2000-07-20) cited in the application  page 97 - page 98; claims; example IIII page 115 page 13, line 19  -----	1,5,8, 11-14, 17,20, 21,24, 25,28-30
Y	CANAN KOCH S S ET AL: "Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal Structure" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 45, 2002, pages 4961-4974, XP002304613 ISSN: 0022-2623 page 4966, left-hand column; figures 2-4; tables 1,3; compounds 24,25,26  -----	1,4,5,8, 11-14, 17,20, 21,24, 25,28-30

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/003183

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 30-32 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/GB2004/003183

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0116136	A	08-03-2001	AU 7338900 A	26-03-2001
			BG 106562 A	31-03-2003
			BR 0015051 A	25-06-2002
			CA 2382404 A1	08-03-2001
			CN 1384835 T	11-12-2002
			CZ 20020613 A3	14-08-2002
			EE 200200100 A	16-06-2003
			EP 1208104 A2	29-05-2002
			HU 0202703 A2	28-12-2002
			JP 2003513015 T	08-04-2003
			MA 25876 A1	01-10-2003
			NO 20020421 A	25-04-2002
			NZ 516793 A	26-03-2004
			PL 354242 A1	29-12-2003
			SK 2592002 A3	08-10-2002
			WO 0116136 A2	08-03-2001
			US 6548494 B1	15-04-2003
			ZA 200200830 A	30-01-2003
WO 0042040	A	20-07-2000	AT 261963 T	15-04-2004
			AU 2408800 A	01-08-2000
			BG 105811 A	31-05-2002
			BR 0008614 A	16-10-2001
			CA 2360003 A1	20-07-2000
			CN 1342161 T	27-03-2002
			CZ 20012443 A3	13-02-2002
			DE 60009033 D1	22-04-2004
			DE 60009033 T2	05-08-2004
			DK 1140936 T3	21-06-2004
			EE 200100364 A	15-10-2002
			EP 1140936 A1	10-10-2001
			ES 2218110 T3	16-11-2004
			HK 1040992 A1	10-09-2004
			HU 0105414 A2	29-05-2002
			ID 30138 A	08-11-2001
			JP 2002534523 T	15-10-2002
			LT 2001083 A ,B	25-03-2002
			LV 12770 A ,B	20-12-2001
			NO 20013313 A	10-09-2001
			NZ 512731 A	30-01-2004
			PL 357049 A1	12-07-2004
			PT 1140936 T	30-06-2004
			SI 20691 A	30-04-2002
			SK 9662001 A3	04-04-2002
			TR 200102005 T2	21-12-2001
			WO 0042040 A1	20-07-2000
			US 2003078254 A1	24-04-2003
			US 6495541 B1	17-12-2002
			ZA 200105399 A	01-07-2002